ArticleDiscover oncology2026
Impact of immune microenvironment on immune checkpoint inhibitor response in HER2-overexpressing urothelial carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe biological interaction between human epidermal growth factor receptor 2 (HER2) overexpression and the tumor immune microenvironment (TIME) in urothelial carcinoma (UC) has not been comprehensively elucidated, which limits the rational integration of HER2-targeted therapies with Immune checkpoint Inhibitors (ICIs). This study aimed to characterize the immune landscape associated with HER2 expression and evaluate its clinical implications.
methodsUsing transcriptomic datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), patients were stratified based on an exploratory threshold, with the highest 20% of ERBB2 mRNA expression defined as HER2-high. Integrated bioinformatic analyses were validated via immunohistochemistry (IHC) in 21 UC specimens. Additionally, a real-world cohort of 29 patients with locally advanced or metastatic UC (la/mUC) treated with disitamab vedotin (RC48), as monotherapy or combined with PD-1 inhibitors, was evaluated for clinical efficacy.
resultsIn this exploratory analysis, HER2-high tumors were associated with an immunologically suppressed phenotype, characterized by reduced immune/stromal infiltration and increased tumor purity. Notably, these tumors exhibited a selective enrichment of FOXP3 + regulatory T cells (Tregs) (P < 0.001) alongside significantly lower expression of canonical immune checkpoints, including CTLA-4, PD-1, and PD-L2 (all P < 0.001). These findings suggest a distinct immune regulatory pattern characterized by regulatory cell enrichment and relatively low expression of classical immune checkpoint molecules.
conclusionsHER2 expression in urothelial carcinoma was associated with a distinct immune microenvironmental profile characterized by Treg enrichment and relatively low immune checkpoint expression, as supported by our protein-level validation. These findings provide additional biological context for the potential therapeutic benefit of combining RC48 with ICIs. Given the exploratory nature of the HER2-high definition and the limited sample size of the validation cohorts, further prospective studies are warranted to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.